News
MYNZ
0.2075
-2.31%
-0.0049
Weekly Report: what happened at MYNZ last week (1111-1115)?
Weekly Report · 5d ago
Mainz Biomed Considers Reverse Stock Split for Nasdaq Compliance
TipRanks · 11/15 22:40
The Oncology Bet Is Already Paying Off For Pfizer
Benzinga · 11/14 00:23
Mainz Biomed Partners with Thermo Fisher for Cancer Screening
TipRanks · 11/12 15:39
Mainz Biomed, Thermo Fisher sign collaboration agreement
TipRanks · 11/12 14:15
Weekly Report: what happened at MYNZ last week (1104-1108)?
Weekly Report · 11/11 09:52
Mainz Biomed files to sell 30.77M ordinary shares
TipRanks · 11/05 13:06
Weekly Report: what happened at MYNZ last week (1028-1101)?
Weekly Report · 11/04 09:51
Weekly Report: what happened at MYNZ last week (1021-1025)?
Weekly Report · 10/28 09:48
Mainz Biomed B.V. GAAP EPS of -$0.49, revenue of $520.77M
Seeking Alpha · 10/21 17:34
Mainz Biomed Highlights Growth and Innovations for 2025
TipRanks · 10/21 12:50
Mainz Biomed restructured operations, implemented cost reductions
TipRanks · 10/21 12:10
Mainz Biomed reports 1H EPS (48c) vs. ($1.00) last year
TipRanks · 10/21 12:05
Weekly Report: what happened at MYNZ last week (1014-1018)?
Weekly Report · 10/21 09:47
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Barchart · 10/21 07:01
Mainz Biomed Sees Revenue Growth Amid Cost Reductions
TipRanks · 10/18 20:28
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 10/15 16:32
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 10/15 12:08
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/14 16:30
Weekly Report: what happened at MYNZ last week (1007-1011)?
Weekly Report · 10/14 09:57
More
Webull provides a variety of real-time MYNZ stock news. You can receive the latest news about Mainz Biomed NV through multiple platforms. This information may help you make smarter investment decisions.
About MYNZ
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.